Catégorie : News_Scientific
-
Advanced BioDesign Strengthens Early Access Program Outcomes, Confirms Steady Progress of ODYSSEY Clinical Trial, and Announces Upcoming Scientific Presentations
Lyon, France – 23rd of March 2026 — Advanced BioDesign, a biotechnology company developing first‑in‑class ALDH1 inhibitors for treatment‑resistant cancers, today released an update on the progress of its Early Access Program (EAP), the advancement of its ODYSSEY first‑in‑human clinical trial, and the participation of its clinical investigators in upcoming scientific conferences. Strong performance of…
-
Advanced BioDesign to Present Groundbreaking Research data on AML at the 67th ASH Annual Meeting
Lyon, France – December 5th, 2025 — Advanced BioDesign, a French clinical-stage biotechnology company focused on developing innovative therapies for treatment-resistant cancers, is proud to announce its participation at the American Society of Hematology (ASH) Annual Meeting 2025 with two significant scientific contributions. Oral Presentation Title: Anthracyclines induce epigenetic changes in ALDH1A that promote chemoresistance…
-
Advanced BioDesign Announces Publication in HemaSphere Uncovering Novel Mechanism Driving Chemoresistance in Acute Myeloid Leukemia
Lyon, France – November 6th, 2025 – Advanced BioDesign, a French clinical-stage biotechnology company focused on developing innovative therapies for treatment-resistant cancers, today announced the publication of its latest research in HemaSphere, the official journal of the European Hematology Association. The article, titled “Upregulation of ALDH1 as an adaptive epigenetic response to anthracyclines in acute…
Advanced BioDesign 